TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.
Also called NCT01970215
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 364 participants
- Sponsor
- Xention Ltd
- Registry
-
NCT01970215 -
2012-005643-24
-
- Other papers using this trial's data
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
- Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01970215. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
- Acronym
- TULIP
- Condition
- Dyslipidemia
- Intervention (Drug)
- TA-8995
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- TA-8995 0mg (placebo)
- Intervention (Drug)
- Placebo Statin
- Lead sponsor
- Xention Ltd
Record details
- Record id
cardio:ct-nct01970215- Content hash
fdadd3ada41d3fe0a9105ea10b39389d7301aadbaa3e2f99ec0426fe52195f09